Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. operates as a clinical-stage biotech firm developing targeted radiotherapies, a narrow field within oncology. Its lead program, Iomab-B, targets acute myeloid leukemia prior to bone marrow transplant. The firm's technology platform uses monoclonal antibodies to deliver radioisotopes directly to cancer cells, aiming to reduce systemic toxicity compared to traditional chemotherapy. Key programs include Iomab-B and Actimab-A, both in clinical trials for hematologic cancers. The firm's strategy involves advancing its pipeline through regulatory milestones, with a focus on Phase 3 trials for Iomab-B. It has generated data from the Phase 3 SIERRA trial, which published in 2023, showing improved outcomes in relapsed or refractory AML patients. Financially, the firm has funded operations through public stock offerings and partnerships, such as a collaboration with the National Cancer Institute for preclinical work. Geographic scope is US-centric, with headquarters in New York City and operations concentrated domestically. Team size is modest, with under 50 employees based on public disclosures (per SEC filings, 2024). The firm does not disclose a separate family office structure publicly; it reports as a public company (NYSE American: ATNM). Recent activity includes the appointment of a new CEO in 2024 to oversee regulatory filings (per company press release, June 2024). Adjacent vehicles are not identified beyond the single corporate entity. A structural differentiator is Actinium's sole focus on targeted alpha therapy, a less-competitive area than broader radiopharmaceuticals. While not a traditional family office, the firm's concentrated pipeline in one modality creates a high-risk, high-reward profile. Governance follows public-company norms, with a board including oncologists and former FDA officials, aligning with its development-stage focus.